title: An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction.
abstract: BACKGROUND
  Exercise-induced bronchoconstriction (EIB) describes acute airway narrowing that occurs as a result of exercise. EIB occurs in a substantial proportion of patients with asthma, but may also occur in individuals without known asthma.
  
  
  METHODS
  To provide clinicians with practical guidance, a multidisciplinary panel of stakeholders was convened to review the pathogenesis of EIB and to develop evidence-based guidelines for the diagnosis and treatment of EIB. The evidence was appraised and recommendations were formulated using the Grading of Recommendations, Assessment, Development, and Evaluation approach.
  
  
  RESULTS
  Recommendations for the treatment of EIB were developed. The quality of evidence supporting the recommendations was variable, ranging from low to high. A strong recommendation was made for using a short-acting β(2)-agonist before exercise in all patients with EIB. For patients who continue to have symptoms of EIB despite the administration of a short-acting β(2)-agonist before exercise, strong recommendations were made for a daily inhaled corticosteroid, a daily leukotriene receptor antagonist, or a mast cell stabilizing agent before exercise.
  
  
  CONCLUSIONS
  The recommendations in this Guideline reflect the currently available evidence. New clinical research data will necessitate a revision and update in the future.
authors: Jonathan P
authors: JP
authors: Parsons
authors: Teal S
authors: TS
authors: Hallstrand
authors: John G
authors: JG
authors: Mastronarde
authors: David A
authors: DA
authors: Kaminsky
authors: Kenneth W
authors: KW
authors: Rundell
authors: James H
authors: JH
authors: Hull
authors: William W
authors: WW
authors: Storms
authors: John M
authors: JM
authors: Weiler
authors: Fern M
authors: FM
authors: Cheek
authors: Kevin C
authors: KC
authors: Wilson
authors: Sandra D
authors: SD
authors: Anderson
mesh_terms: D000280:Administration, Inhalation; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001250:Asthma, Exercise-Induced / Q000175:diagnosis / Q000188:drug therapy / Q000517:prevention & control; D019317:Evidence-Based Medicine; D006801:Humans; D020024:Leukotriene Antagonists / Q000627:therapeutic use*
chemical_list: D000318:Adrenergic beta-Agonists; D018927:Anti-Asthmatic Agents; D020024:Leukotriene Antagonists